Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00250419 | V930 First in Man (FIM) Study (V930-002)(COMPLETED) | PHASE1 | COMPLETED | 26 | — | — | Sep 1, 2005 | Sep 1, 2008 | Feb 10, 2015 | - | — |
| Name | Type | Description |
|---|---|---|
| V930 | BIOLOGICAL | - |
Inclusion Criteria: * Patients must have stages II, III, or IV breast, colorectal, ovaria, of non-small cell lung cancer * Patients will either be disease free following primary therapy or have advanced disease with a durable response (\>3 months) after standard therapy * Tumor antigen HER-2 and/or...